Michael P. Kosty

4.7k total citations
74 papers, 3.4k citations indexed

About

Michael P. Kosty is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael P. Kosty has authored 74 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael P. Kosty's work include Advances in Oncology and Radiotherapy (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Economic and Financial Impacts of Cancer (12 papers). Michael P. Kosty is often cited by papers focused on Advances in Oncology and Radiotherapy (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Economic and Financial Impacts of Cancer (12 papers). Michael P. Kosty collaborates with scholars based in United States, France and Italy. Michael P. Kosty's co-authors include Amy Hanley, Suanna S. Bruinooge, James E. Herndon, Michael A. Goldstein, Dean F. Bajorin, Mark R. Green, Alan Saven, Lawrence D. Piro, Stewart B. Fleishman and Ernest Beutler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Michael P. Kosty

73 papers receiving 3.3k citations

Peers

Michael P. Kosty
Paul Cockwell United Kingdom
Amanda L. Blackford United States
Marc Botteman United States
John A. Levi Australia
Gustaf Edgren Sweden
Paul Sabbatini United States
Tomohiro Matsuda Japan
Smita Bhatia United States
Claudia Allemani United Kingdom
Franz Porzsolt Germany
Paul Cockwell United Kingdom
Michael P. Kosty
Citations per year, relative to Michael P. Kosty Michael P. Kosty (= 1×) peers Paul Cockwell

Countries citing papers authored by Michael P. Kosty

Since Specialization
Citations

This map shows the geographic impact of Michael P. Kosty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Kosty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Kosty more than expected).

Fields of papers citing papers by Michael P. Kosty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Kosty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Kosty. The network helps show where Michael P. Kosty may publish in the future.

Co-authorship network of co-authors of Michael P. Kosty

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Kosty. A scholar is included among the top collaborators of Michael P. Kosty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Kosty. Michael P. Kosty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
New, Jacob, et al.. (2024). Pluvicto in the real world setting and timing to PSA50 as a predictive marker of treatment response.. Journal of Clinical Oncology. 42(16_suppl). e17026–e17026. 1 indexed citations
2.
Čufer, Tanja, et al.. (2023). ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. JCO Global Oncology. 9(9). e2300277–e2300277. 9 indexed citations
3.
Ensign, Shannon P. Fortin, Kathryn Bollin, Sherri Z. Millis, et al.. (2019). Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. Pigment Cell & Melanoma Research. 33(3). 458–465. 2 indexed citations
4.
Bruinooge, Suanna S., Todd Pickard, Wendy Vogel, et al.. (2018). Understanding the role of advanced practice providers in oncology in the United States. JAAPA. 31(12). 1–12. 8 indexed citations
5.
Rothenstein, J., Alexander I. Spira, Vamsidhar Velcheti, et al.. (2018). P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab. Journal of Thoracic Oncology. 13(10). S495–S495. 3 indexed citations
6.
Bruinooge, Suanna S., Todd Pickard, Wendy Vogel, et al.. (2018). Understanding the Role of Advanced Practice Providers in Oncology in the United States. Oncology nursing forum. 45(6). 786–800. 3 indexed citations
7.
Cortinovis, Diego, Joachim von Pawel, K. Syrigos, et al.. (2017). Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK. Annals of Oncology. 28. v468–v468. 4 indexed citations
8.
Pawel, Joachim von, K. Syrigos, Julien Mazières, et al.. (2017). Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Annals of Oncology. 28. v469–v469. 28 indexed citations
9.
Woźniak, Agnieszka, Michael P. Kosty, Mohammad Jahanzeb, et al.. (2015). Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study. Clinical Oncology. 27(4). 187–196. 21 indexed citations
10.
Shanafelt, Tait D., Marilyn Raymond, Leora Horn, et al.. (2014). Oncology Fellows' Career Plans, Expectations, and Well-Being: Do Fellows Know What They Are Getting Into?. Journal of Clinical Oncology. 32(27). 2991–2997. 46 indexed citations
11.
Gollard, Russell, et al.. (2010). Large cell/neuroendocrine carcinoma. Lung Cancer. 69(1). 13–18. 33 indexed citations
12.
Gordon, Robert T., et al.. (2008). The Use of Canines in the Detection of Human Cancers. The Journal of Alternative and Complementary Medicine. 14(1). 61–67. 107 indexed citations
13.
Lima, Caio Max S. Rocha, James E. Herndon, Michael P. Kosty, Gerald H. Clamon, & Mark R. Green. (2001). Therapy choices among older patients with lung carcinoma. Cancer. 94(1). 181–187. 118 indexed citations
14.
Kosty, Michael P., James E. Herndon, Nicholas J. Vogelzang, Hedy L. Kindler, & Mark R. Green. (2001). High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study—Cancer and Leukemia Group B 9631. Lung Cancer. 34(2). 289–295. 14 indexed citations
15.
Meisenberg, BR, William E. Miller, R McMillan, et al.. (1997). Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies.. Journal of Clinical Oncology. 15(1). 11–17. 55 indexed citations
16.
Saven, Alan, et al.. (1996). Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 14(7). 2139–2144. 39 indexed citations
17.
Elias, Darlene J., Lawrence E. Kline, Bruce A. Robbins, et al.. (1994). Monoclonal Antibody KS1/4-Methotrexate Immunoconjugate Studies in Non-Small Cell Lung Carcinoma. American Journal of Respiratory and Critical Care Medicine. 150(4). 1114–1122. 33 indexed citations
18.
19.
Saven, Alan, Hajime Kawasaki, T A Waltz, et al.. (1993). 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.. Journal of Clinical Oncology. 11(4). 671–678. 41 indexed citations
20.
Anderson, James R., David Cella, Susan Tross, et al.. (1992). Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer. 70(10). 2508–2516. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Cockwell Breakdown of academic impact, for papers by Amanda L. Blackford Breakdown of academic impact, for papers by Marc Botteman Breakdown of academic impact, for papers by John A. Levi Breakdown of academic impact, for papers by Gustaf Edgren Breakdown of academic impact, for papers by Paul Sabbatini Breakdown of academic impact, for papers by Tomohiro Matsuda Breakdown of academic impact, for papers by Smita Bhatia Breakdown of academic impact, for papers by Claudia Allemani Breakdown of academic impact, for papers by Franz Porzsolt
Rankless by CCL
2026